Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Increases By 20.0%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 232,100 shares, an increase of 20.0% from the January 15th total of 193,400 shares. Currently, 3.0% of the company’s stock are sold short. Based on an average daily trading volume, of 72,900 shares, the days-to-cover ratio is currently 3.2 days.

Marker Therapeutics Stock Performance

Shares of Marker Therapeutics stock traded up $0.02 during midday trading on Monday, hitting $1.72. The company’s stock had a trading volume of 61,990 shares, compared to its average volume of 78,471. The stock has a 50-day simple moving average of $2.81 and a 200-day simple moving average of $3.18. Marker Therapeutics has a 1-year low of $1.48 and a 1-year high of $5.99.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Brookline Capital Management raised shares of Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th. LADENBURG THALM/SH SH increased their price objective on Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, October 21st.

Insider Activity

In related news, Director Steve Elms acquired 11,085 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the purchase, the director now directly owns 325,370 shares in the company, valued at $1,041,184. This represents a 3.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Enterprise Associates 16 New bought 554,250 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the purchase, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. The trade was a 51.73 % increase in their position. The disclosure for this purchase can be found here. Insiders own 17.35% of the company’s stock.

Hedge Funds Weigh In On Marker Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Alyeska Investment Group L.P. bought a new position in Marker Therapeutics during the fourth quarter valued at about $2,847,000. Blue Owl Capital Holdings LP acquired a new position in Marker Therapeutics during the 4th quarter valued at $1,724,000. LPL Financial LLC acquired a new stake in Marker Therapeutics in the 4th quarter worth $248,000. Northern Trust Corp increased its holdings in shares of Marker Therapeutics by 66.9% during the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after purchasing an additional 21,703 shares during the period. Finally, Invst LLC acquired a new position in shares of Marker Therapeutics during the third quarter valued at about $56,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.